FibroGen (FGEN) Says FDA Advisory Committee Voted to Recommend Not Approving Roxadustat
- Stocks pause as key inflation data eyed
- Citi says S&P 500 not in a bubble, tells investors to 'buy pullbacks'
- eBay delivers upbeat guidance, Q4 results top estimates; unveils $2B stock buyback
- JPMorgan's Kolanovic says the S&P 500 rally is at risk from a narrative shift
- Apple (AAPL) discontinues its electric car project, redirects team to focus on GenAI
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. The Committee based its recommendation on data from a global Phase 3 program encompassing more than 8,000 patients. While the FDA is not required to follow the Committee's vote, the agency considers the Committee's non-binding recommendations when making its decision.
“While we are disappointed with today's outcome,” said Enrique Conterno, Chief Executive Officer, FibroGen, “we believe the scientific evidence supports roxadustat approval in the U.S. and will work with the FDA as it completes its review of the New Drug Application for roxadustat.”
Roxadustat is approved in China, Japan, Chile, and South Korea for the treatment of anemia of CKD in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) adult patients and has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency’s committee responsible for human medicines. Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD. Roxadustat has the potential to transform treatment for anemia of CKD.
Anemia of CKD is a condition in which people have insufficient red blood cells, which reduces oxygen delivery throughout the body.1 Anemia becomes increasingly common among patients with CKD as the disease progresses whether or not they are on dialysis.2
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Minerva Neurosciences (NERV) Receives CRL from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
- Hoth Therapeutics Inc. (HOTH) Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
- Orchestra BioMed (OBIO) Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy f
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Hot FDA News
Related EntitiesAdCom, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!